Current Assets (USD, thousands)

Cash and Cash Equivalents (USD, thousands)

Accounts Receivable (USD, thousands)

Inventory (USD, thousands)

Non-Current Assets (USD, thousands)

Property, Plant, and Equipment (PP&E) (USD, thousands)

Goodwill (USD, thousands)

Intangible Assets (USD, thousands)

Current Liabilities (USD, thousands)

Accounts Payable (USD, thousands)

Short-term Debt (USD, thousands)

Accrued Expenses (USD, thousands)

Non-Current Liabilities (USD, thousands)

Long-term Debt (USD, thousands)

Lease Liabilities (USD, thousands)

Deferred Tax Liabilities (USD, thousands)

Shareholders' Equity (USD, thousands)

Retained Earnings (USD, thousands)

Common Stock (USD, thousands)

Additional Paid-in Capital (USD, thousands)

c6ff2b446a000d502208dbfd72d8fd71d78f1b95fc3d76a44a4fc0fe8a922b03

Total Revenue (USD, thousands)

Cost of Goods Sold (COGS) (USD, thousands)

SG&A (USD, thousands)

R&D (USD, thousands)

D&A (USD, thousands)

Interest Expense (USD, thousands)

Operating Income (EBIT) (USD, thousands)

Net Income (USD, thousands)

EPS - Basic (USD/share)

EPS - Diluted (USD/share)

f4d50627c7b3e43287a3291b415704cf593609c456217c5bcd514d2a2fdfbc6f

Adjustments for Non-Cash Items (USD, thousands)

Stock-Based Compensation (USD, thousands)

Changes in Working Capital (USD, thousands)

Capital Expenditures (CapEx) (USD, thousands)

Proceeds from / Repayments of Debt (USD, thousands)

Share Repurchases (USD, thousands)

Dividend Payments (USD, thousands)

Net Change in Cash (USD, thousands)

7597688cb8355d7f397f2726c2763627e0a7c043c8f926c6b8cefc5fae9dac5e

Cash and cash equivalents (USD, thousands)

Short-term marketable securities (USD, thousands)

Prepaid expenses and other current assets (USD, thousands)

Total current assets (USD, thousands)

Prepaid expenses and other assets, non-current (USD, thousands)

Operating lease right-of-use asset (USD, thousands)

Property, plant and equipment, net (USD, thousands)

Restricted cash (USD, thousands)

Total assets (USD, thousands)

Accounts payable (USD, thousands)

Accrued research and development expenses (USD, thousands)

Accrued compensation and other current liabilities (USD, thousands)

Severance liability (USD, thousands)

Total current liabilities (USD, thousands)

Operating lease liability, non-current (USD, thousands)

Total liabilities (USD, thousands)

Common stock (USD, thousands)

Additional paid-in capital (USD, thousands)

Accumulated other comprehensive income (loss) (USD, thousands)

Accumulated deficit (USD, thousands)

Total stockholders’ equity (USD, thousands)

Total liabilities, redeemable convertible preferred stock and stockholders’ equity (USD, thousands)

b303fdeb9f9bb256e0d5f7696bd7bf308ad0b3af8f48091217a63ba332f7639c

Net cash used in operating activities (USD, thousands)

Net cash provided by investing activities (USD, thousands)

Net cash provided by financing activities (USD, thousands)

Net increase (decrease) in cash, cash equivalents and restricted cash (USD, thousands)

Net loss (USD, thousands)

Stock-based compensation expense (USD, thousands)

Income from sale of asset (USD, thousands)

Net amortization of premiums and accretion of discounts on marketable securities (USD, thousands)

Loss on disposal of property, plant and equipment (USD, thousands)

Proceeds from sale of asset (USD, thousands)

Purchase of marketable securities (USD, thousands)

Proceeds from maturities of short-term marketable securities (USD, thousands)

Sales of marketable securities (USD, thousands)

Purchase of property, plant and equipment (USD, thousands)

Proceeds from exercise of common stock options and issuance of common stock upon settlement of restricted stock unites, net of shares withheld for taxes, and under the employee stock purchase plan (USD, thousands)

Cash, cash equivalents and restricted cash at beginning of period (USD, thousands)

Cash, cash equivalents and restricted cash at end of period (USD, thousands)

69835f96cc3344de794534050a36c52a103fe8fcb1a595286d23b3f028bd2294

Research and Development Expenses (USD, thousands)

General and Administrative Expenses (USD, thousands)

Total Operating Expenses (USD, thousands)

Loss from Operations (USD, thousands)

Change in Fair Value of Derivative Tranche Liability (USD, thousands)

Interest Income (USD, thousands)

Other Income (Expense), Net (USD, thousands)

Net Loss (USD, thousands)

Unrealized Gain (Loss) on Short-term Marketable Securities, Net (USD, thousands)

Total Other Comprehensive Gain (Loss) (USD, thousands)

Net Loss and Other Comprehensive Loss (USD, thousands)

Net Loss per Share Attributable to Common Stockholders, Basic and Diluted (USD)

Weighted-Average Common Shares Outstanding, Basic and Diluted

044162501a78fd2c5952802e3f341c11113fd12eaffba9c9996d63f5d34be530

ACELYRIN, Inc. (SLRN)

Financials